Investor Relations
Mar 21, 2019
OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial MORE >>
Feb 27, 2019
OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results MORE >>
Feb 26, 2019
OPKO Health to Announce Fourth Quarter 2018 Financial Results on February 27, 2019 MORE >>
Feb 05, 2019
OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes MORE >>

Press Releases

All Releases
OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial
Mar 21, 2019
OPKO Health’s Oxyntomodulin, OPK88003, Shows Significant Reduction in HbA1c and Body Weight in Patients with Type 2 Diabetes MIAMI , March 21, 2019 (GLOBE NEWSWIRE) -- OPKO Health , Inc. (NASDAQ: OPK) today announced positive topline results from a Phase 2 dose escalation trial of OPK88003 to treat
OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results
Feb 27, 2019
Conference Call begins today at 4:30 p.m. Eastern Time MIAMI , Feb. 27, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2018 . Business Highlights RAYALDEE total prescriptions reported by IQVIA
OPKO Health to Announce Fourth Quarter 2018 Financial Results on February 27, 2019
Feb 26, 2019
MIAMI , Feb. 26, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to announce its operating and financial results for the three and twelve months ended December 31, 2018 as well as provide guidance on expected revenues and operating expenses for the first quarter 2019 after the close
OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes
Feb 05, 2019
MIAMI , Feb. 05, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (“ OPKO Health” or the “Company”) (NASDAQ: OPK) today announced the pricing of its offering of $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”). The Notes will be general senior unsecured
OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes
Feb 04, 2019
MIAMI , Feb. 04, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (“ OPKO Health” or the “Company”) (NASDAQ: OPK) today announced that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”) in an underwritten
OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer
Feb 01, 2019
MIAMI , Feb. 01, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration ( FDA ) has approved the Company’s point-of-care Sangia Total Prostate Specific Antigen ( PSA ) Test using the Claros 1 Analyzer.  The product is indicated to
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator
Jan 31, 2019
MIAMI , Jan. 31, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced an update on the ongoing development plans of OPK-88004, a selective androgen receptor modulator (SARM). OPK-88004 has the ability to serve as an antagonist to androgen receptors in the prostate, resulting in
Future Non-Coverage Determination for 4Kscore Test Posted by Novitas
Jan 31, 2019
MIAMI , Jan. 31, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that Novitas Solutions, Inc. has issued a notice of a future non-coverage determination for the 4Kscore test® to be effective March 20, 2019 . The notice released by Novitas today does not appear to be
OPKO Health Appoints Jon R. Cohen, M.D. Executive Chairman of BioReference Laboratories
Jan 07, 2019
Geoff Monk promoted to President MIAMI , Jan. 07, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Jon R. Cohen , M.D. as Executive Chairman of BioReference Laboratories . BioReference, with its GeneDx unit, is the third largest clinical laboratory in the
OPKO Health and OPKO's CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action
Dec 27, 2018
Frost to continue as CEO and Chairman of OPKO MIAMI , Dec. 27, 2018 /PRNewswire/ -- In a settlement, subject to court approval, OPKO Health , Inc. (NASDAQ: OPK) and OPKO's CEO and Chairman, Dr. Phillip Frost , have agreed with the Securities and Exchange Commission to resolve the action brought
OPKO Health Reports Third Quarter 2018 Financial Results
Nov 09, 2018
Conference Call begins today at 4:15 p.m. Eastern Time MIAMI , Nov. 09, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports financial results and business highlights for the three months ended September 30, 2018 . Financial Highlights Net loss for the three months ended September 30,
BioReference Laboratories Named as Preferred Laboratory with Horizon Healthcare Services
Nov 08, 2018
MIAMI , Nov. 08, 2018 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc.  (BRL) , an  OPKO Health  (NASDAQ: OPK) company and the third largest clinical laboratory in the United States , will remain an in-network provider with Horizon Health Services, Inc.
OPKO Health to Announce Third Quarter 2018 Financial Results on November 9, 2018
Nov 08, 2018
MIAMI , Nov. 08, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to announce its operating and financial results for the three and nine months ended September 30, 2018 after the close of the U.S. financial markets on Friday, November 9, 2018 .
OPKO Confirms Resumption of Common Stock Trading on Nasdaq
Sep 14, 2018

MIAMI --(BUSINESS WIRE)--Sep. 14, 2018-- OPKO Health, Inc. (NASDAQ: OPK) is pleased to confirm that The Nasdaq Stock Market has lifted the trading suspension of OPKO’s shares. As noted previously, OPKO and 19 other defendants, including Dr. Phillip Frost , its CEO and Chairman, were named in a

OPKO Comments on Continued Nasdaq Halt of Trading of Common Stock
Sep 11, 2018

MIAMI --(BUSINESS WIRE)--Sep. 11, 2018-- OPKO Health, Inc. (NASDAQ:OPK) has had trading in its common stock halted by The Nasdaq Stock Market , and the exchange has advised OPKO that the halt will continue until the company responds (to Nasdaq’s satisfaction) to the exchange’s request for

OPKO Comments on SEC Complaint
Sep 07, 2018

MIAMI --(BUSINESS WIRE)--Sep. 7, 2018-- OPKO Health, Inc. (NASDAQ: OPK) provided the following comment on the lawsuit filed by the U.S. Securities and Exchange Commission earlier today. “OPKO learned today that the Securities and Exchange Commission has filed a lawsuit in the Southern District of

OPKO Initiates RAYALDEE Phase 2 Trial in Dialysis Patients
Sep 04, 2018

MIAMI , Sept. 04, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) has initiated a Phase 2 clinical trial to study the safety and efficacy of RAYALDEE ® as a new treatment for secondary hyperparathyroidism (SHPT) in adults with vitamin D insufficiency and stage 5 chronic kidney disease

OPKO Health’s BioReference Laboratories to Participate in the National Cancer Institute NCI-MATCH (Molecular Analysis for Therapy Choice) Phase II Clinical Trial
Aug 28, 2018

MIAMI , Aug. 28, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that BioReference Laboratories, Inc. (BRL), an OPKO Health company and the third largest clinical laboratory in the United States , has signed a collaboration agreement with the National Cancer Institute (NCI)

OPKO Health Reports Second Quarter 2018 Financial Results
Aug 07, 2018

Conference Call begins today at 4:30 p.m. Eastern Time MIAMI , Aug. 07, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports financial results and business highlights for the three months ended June 30, 2018 . Financial Highlights Net loss for the quarter decreased by 63% to $6.2 million

OPKO Health Completes Enrollment in Global Phase 3 Study of Somatrogon (hGH-CTP) in Growth Hormone Deficient Children
Aug 03, 2018

MIAMI , Aug. 03, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) has completed enrollment in the Company’s global pivotal Phase 3 study in growth hormone deficient children, evaluating a single weekly injection of its investigational long-acting human growth hormone product, somatrogon,

Displaying 1 - 20 of 376